PRESIDENT ENDOCRINE TECHNOLOGY, LLC NY, New York, United States
Abstract Text: The Problem: Currently there are no approved drugs in Covid-19 infection to target immune pathogenesis of Covid-19 that includes dysfunction of alternate complement system (Jia Yu, Gloria et al "Complement dysregulation is associated with severe COVID-19 illness" Haematologica 2022; Volume 107(5):1095-1105
Method: We developed nano sulfonic polymers for balanced targeting of Factor D.
Results: This will a. inhibit immune piracy of factor H; b. Inhibit hyper activated alternate complement system due to factor D and c. reduced adverse effects of factor h. Discussions: Based on extensive Human safety record generated - sulfonic polymers may provide an ideal immune modulation therapy. This can be rapidly integrated in to evolving standards of covid-19 therapies covering prevention, prophylaxis and therapy of Covid-19 infection.
